AVM Biotechnology Expands C-Suite in Anticipation of 2023 Commercialization Efforts
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
FDA Approves Accelerated Dosing in Non-Hodgkin s Lymphoma/Leukemia Clinical Trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
By oracknows on April 4, 2017.
Last week, I took note of something that antivaxers hadn t done in nine years, specifically a march on Washington. Back in 2008, Jenny McCarthy and her then-boyfriend Jim Carrey led a rag tag rogues gallery of antivaccine activists on a march and rally that they called Green Our Vaccines. The name of the rally, of course, derived from a common trope beloved of antivaccine activists that I like to refer to as the toxin gambit. It s basically a Food Babe-like fear of those evil chemicals writ large in a claim that vaccines are packed full of horrific chemicals that are Making Our Babies Autistic and/or making them asthmatic, diabetic, or even dying of sudden infant death syndrome. It s a profoundly scientifically ignorant gambit in that the dose makes the poison and the amount of the various scary-sounding chemicals to which antivaxers like to point in vaccines is tiny and safe. For instance, antivaxers love to point to formald
Share this article
Share this article
SEATTLE, April 7, 2021 /PRNewswire/ AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical study (NCT04329728 The WWRD Study ). All three patients had failed multiple prior therapies, and one had failed two transplants. These patients are reportedly all doing very well, and one was quoted as saying, I feel great! Three major US Cancer Centers are actively enrolling study participants. AVM Biotechnology is excited to advance AVM0703 to the next dose level cohort of no-option lymphoma patients. The drug has been well tolerated, without safety issues, as expected. The study is an adaptive design/expansion cohort trial such that cohort enrollment of relapsed/refractory Non-Hodgkin s Lymphoma patients for the pivotal trial can immediately follow the dose-escalation phase.